UK Markets closed
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • FTSE 250

    20,615.59
    -160.21 (-0.77%)
     
  • AIM

    1,173.12
    -10.50 (-0.89%)
     
  • GBP/EUR

    1.1248
    +0.0033 (+0.29%)
     
  • GBP/USD

    1.3583
    -0.0057 (-0.4143%)
     
  • BTC-GBP

    26,719.57
    +387.64 (+1.47%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • DOW

    30,814.26
    -177.24 (-0.57%)
     
  • CRUDE OIL

    52.04
    -1.53 (-2.86%)
     
  • GOLD FUTURES

    1,827.70
    -23.70 (-1.28%)
     
  • NIKKEI 225

    28,519.18
    -179.12 (-0.62%)
     
  • HANG SENG

    28,573.86
    +76.96 (+0.27%)
     
  • DAX

    13,787.73
    -200.97 (-1.44%)
     
  • CAC 40

    5,611.69
    -69.45 (-1.22%)
     

Fixing of Coupon Interest Rate

Jyske Realkredit A/S
·1-min read

To Nasdaq Copenhagen A/S 23 December 2020
Announcement no. 123/2020





Fixing of Coupon Interest Rate


Interest rate for Jyske Realkredit's:

Series 422.E.Cb3.21 RF with ISIN DK0009392185 has per 1 January 2021 and until and including 31 March 2021 been set at 0.01 % p.a.

Series 324.E.Cb3.21 RF with ISIN DK0009393829 has per 1 January 2021 and until and including 31 March 2021 been set at -0.20 % p.a.

Series 422.E.Cb3 ju23 RF with ISIN DK0009397499 has per 1 January 2021 and until and including 31 March 2021 been set at -0.19 % p.a.

Series 422.B.Cb3 ju23 RF with ISIN DK0009397572 has per 1 January 2021 and until and including 31 March 2021 been set at -0.11 % p.a.

Series 422.E.Cb3.22 RF with ISIN DK0009392508 has per 1 January 2021 and until and including 31 March 2021 been set at -0.11 % p.a.

Series 422.E.OA.Cb3.ju24 RF with ISIN DK0009403560 has per 1 January 2021 and until and including 31 March 2021 been set at -0.08 % p.a.

Questions may be addressed to Christian Bech-Ravn, Head of Investor Relations, tel. (+45) 89 89 92 25.

Best Regards

Jyske Realkredit A/S
Web: jyskerealkredit.dk
Please observe that the Danish version of this announcement prevails.